ArticleJournal of lipids2012
Paraoxonase 1 in chronic kidney failure.
Article in Journal of lipids, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Paraoxonase 1 and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.Molecules (Basel, Switzerland) · 2021Pooled it
- Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome.Cardiovascular drugs and therapy · 2025Article
- Effect of Exercise Repetitions on Arylesterase Activity of PON1 in Plasma of Average-Trained Men-The Dissociation between Activity and Concentration.Antioxidants (Basel, Switzerland) · 2023Article
- Paraoxonase 1 and Chronic Kidney Disease: A Meta-Analysis.Journal of clinical medicine · 2023Article
- Vitamin C supplementation and paraoxonase 1 activity in patients on hemodialysis: a meta-analysis.Archives of medical sciences. Atherosclerotic diseases · 2023Article
- Cardioprotective Role for Paraoxonase-1 in Chronic Kidney Disease.Biomedicines · 2022Article
- The Relationship between Cancer and Paraoxonase 1.Antioxidants (Basel, Switzerland) · 2022Review
- Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis.Antioxidants (Basel, Switzerland) · 2021Review
- Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease.Biomolecules · 2020Review
- Chronic Kidney Disease as Oxidative Stress- and Inflammatory-Mediated Cardiovascular Disease.Antioxidants (Basel, Switzerland) · 2020Review
- Oxidative Stress in Hemodialysis Pediatric Patients.Open access Macedonian journal of medical sciences · 2019Article
- Circulating Lactonase Activity but Not Protein Level of PON-1 Predicts Adverse Outcomes in Subjects with Chronic Kidney Disease.Journal of clinical medicine · 2019Article
- Paraoxonase 1, HDL Subclasses and Post Surgery Acute Inflammation: A Pilot Study.Antioxidants (Basel, Switzerland) · 2019Article
- Article
- Chronic Kidney Disease and Disproportionally Increased Cardiovascular Damage: Does Oxidative Stress Explain the Burden?Oxidative medicine and cellular longevity · 2017Review
- Associations among apolipoproteins, oxidized high-density lipoprotein and cardiovascular events in patients on hemodialysis.PloS one · 2017Article
- Açai (Euterpe oleracea Mart.) Upregulates Paraoxonase 1 Gene Expression and Activity with Concomitant Reduction of Hepatic Steatosis in High-Fat Diet-Fed Rats.Oxidative medicine and cellular longevity · 2016Article
- Evidence for the presence of active paraoxonase 1 in small-dense low-density lipoprotein.Redox report : communications in free radical research · 2014Article
- Paraoxonase-1 gene Q192R and L55M polymorphisms and risk of cardiovascular disease in Egyptian patients with type 2 diabetes mellitus.Journal of diabetes and metabolic disorders · 2014Article
- Potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis.BioMed research international · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review we summarize the findings from the literature and our own laboratory on the decreased PON1 activity in renal failure, the mechanisms proposed and the effect of interventions. In addition to profound alterations in lipoproteins, reduced serum PON1 activity has been clearly established in the past decade and could contribute to accelerated development of atherosclerosis in ESRD and in HD. PON1 lactonase activity is lower in ESRD patients. Hemodialysis partially restores PON1 lactonase and the other activities. PON1 activity recovery after dialysis suggests that uremic toxins may play a mechanistic role in PON1 inactivation. Lower PON1 activity in CRF patients is associated with low thiol concentration, high CRP, and is beneficially enhanced with vitamin C and flavonoids. Changes in HDL subclasses, namely lower HDL(3) in these patients may also play a role in PON1 lower activity. Future research should focus on: (1) mechanistic studies on causes for low PON1 activity and mass; (2) prospective studies focusing on whether there is an added predictive value in measuring PON1 activity (and PON1 activity in HDL(3)) in this patient population; (3) intervention studies attempting to increase PON1 activity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.